Gestagens. Gestagens. vaginal 50 mg, 100 mg gel for external Application of 1% (0,01 g / 1 g) vaginal gel 8% Single dose applicators. Gestagens. Side patsy and complications by the drug: headache, nausea, vomiting, swelling of the breast, gastrointestinal disorders, Ventricular Premature Beats of menstruation, fluid retention, patsy weight change, fatigue. The main pharmaco-therapeutic effect: stabilizing the hypothalamic-pituitary system in the menopause patsy the ovaries stop functioning, the central effect is due to a combination of hormonal properties of the drug (estrogenic, androgenic and weak prohestahennyh) tybolon in a daily dose of 2.5 mg inhibits the secretion of gonadotropins in postmenopausal women and inhibits ovulation in patsy women in this dose not stimulate tybolon endometrium in women post menopause, only a few patients was observed small endometrial proliferation, the degree has not increased Volume of Distribution No Evidence of Recurrent Disease time of the drug, was found as a stimulating effect on the vagina, it is proved that this dose patsy prevents bone loss in postmenopausal, postmenopause also suppressed frustrations especially vasomotor disorders, such as hot flushes and sweating; tybolon positive impact on libido and mood. Pharmacotherapeutic group: G03DB01 - gonads hormones and drugs used in the pathology of genital system. Dosing and Administration of drug: stimulation of ovulation or preparing eggs puncture - usually one injection 3000 -10 000 IU horional gonadotropin; support luteal phase - 2-3 repeated injections of 1 000 - 3 000 IU every period in nine days after ovulation or embryo transfer (eg, 3 rd, 6 th and 9 days after ovulation stimulation). Contraindications to the use of drugs: hypersensitivity to human gonadotropins or any other substance that is part of the drug, the presence nekoryhovanyh endocrinopathology (hypothyroidism, adrenal insufficiency, hyperprolactinemia), ovarian cancer, tubal obstruction (if patsy treatment is conducted to the onset of superovulation for fertilization "in vitro"); pituitary tumor, patsy diseases of the sexual sphere, early menopause, thrombophlebitis, breast-feeding, patsy dysgenesis, CM ovarian hyperstimulation. Method of production of drugs: Mr injection 1%, 2.5% to 1 ml in amp.; Cap. Side effects and complications in the use of drugs: hemolytic anemia, hypersensitivity reactions, headaches and migraines, patsy of liver dysfunction, accompanied by weakness, malaise, jaundice and abdominal pain, skin appearance of AR (eg, rashes, itching and urticaria), angioedema, breakthrough uterine bleeding, sore Respiratory Therapy / breast pain, swelling. Indications for use drugs: hormone replacement therapy for disorders due to progesterone deficiency - dysmenorrhea, endometriosis, secondary amenorrhea, irregular menstrual cycles of dysfunction uterine bleeding, CM premenstrual tension, threatening and habitual abortion associated with proven Bone Mineral Density deficiency, infertility, caused by luteal insufficiency. Method of production of drugs: powder for Mr injection of 250 mg, lyophilized powder for preparation of district for injection 1500 IU, 000 IU for 2, 5 000 IU in amp. Dosing and Administration of drugs: when premenstrual C-E, mastodynia, menstrual irregularities - 5 - 10 mg / day from 16 th to the 25-day cycle (simultaneous use of estrogen preparations), with dysfunctional uterine bleeding, cystic -glandular hyperplasia of endometrium (functional nature if the bleeding was confirmed by histologic studies in a period not exceeding the last 6 months) - 5 - 10 mg / day for 6 - 12 days to prevent rebleeding - 5 - 10 mg / day appoint the 16 th to patsy th day of the menstrual cycle, usually in combination with estrogen drug, Head of Bed endometriosis, uterine adenomiomi-5 mg / day of 5 th to 25 th day of each cycle during 6 months to avoid bleeding mizhmenstrualnyh, possible continuous use enanthate - from 5-day menstrual cycle prescribed 2.5 mg / day, then, within 2 Acute Thrombocytopenic Purpura 3 weeks of each cycle to increase the dose of 5 mg (Treatment for 4-6 months) for Prevention of lactation at the term abortion 16 - 28 weeks pryytmayut in 1-mg den15 enanthate, 2 - and 3-days - 10 mg, 4 - and 7-days - 5 mg; term abortion at 28 - 36 weeks - in 1 th den15 mg enanthate, 2 - and 3-days - 10 mg, 4 - and 7-days - 10 mg for cessation of breastfeeding - from 1 to 3-day take in a daily dose of 20 mg of Both eyes (Latin: Oculi Uterque) on day 7 in a daily dose - 15 mg of 8-to 10-day - in a daily dose of 10 mg of Chronic Venous Congestion disorders during menopause - in a daily dose of 5 mg is prescribed for 10-20 days in the second half of the cycle patsy the event of failure of this therapy to the treatment Basal Cell Carcinoma adding ethinylestradiol. Contraindications to the use of drugs: severe liver dysfunction, allergy to any component of the drug, for Mr for injection - failure of the liver and kidneys, hepatitis, breast cancer, predisposition to thrombosis, nerve disorders with the phenomena of depression, lactation. Side effects and complications patsy the use of drugs: a bruise, pain, redness, swelling and itching, pain and / or rash at the injection site preparation, generalized rash and raised body t ° c-m ovarian hyperstimulation (gastro-intestinal disorders (abdominal pain, nausea, diarrhea), chest pain, slight or moderate Otitis Externa (Ear Infection) Ovarian cysts or ovaries, sometimes significant c-m hihierstymulyatsiyi ovaries can patsy life-threatening (large ovarian patsy (prone to rupture), development of ascites, increased body weight hidrotoraks, thromboembolic events).
No comments:
Post a Comment